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Abstract
Alcoholic liver disease (ALD) is responsible for an average of 50.4% and 44.2%of liver dis-
ease deaths among males and females respectively. Driven by alcohol misuse, ALD is often
reversible by cessation of consumption. However, abstinence programs can have limited
success at curtailing abuse, and the loss of life. ALD, therefore, remains a significant clinical
challenge. There is a need for effective treatments that prevent or reverse alcohol-induced
liver damage to complement or supplant behavioral interventions. Metabolic syndrome,
which is disproportionally prevalent in ALD patients, accelerates the progression of ALD and
increases liver disease mortality. Current rodent models of ALD unfortunately do not
account for the contribution of the western diet to ALD pathology. To address this, we have
developed a rodent model of ALD that integrates the impact of the western diet and alcohol;
the WASH-diet model. We show here that the WASH diet, either chronically or in small time-
restricted bouts, accelerated ALD pathology with severe steatohepatitis, elevated inflamma-
tion and increased fibrosis compared to mice receiving chronic alcohol alone. We also vali-
dated our WASH-diet model as an in vivo system for testing the efficacy of experimental
ALD treatments. The efficacy of the inverse-agonist SR9238, previously shown to inhibit
both non-alcohol and alcohol-induced steatohepatitis progression, was conserved in our
WASH-diet model. These findings suggested that the WASH-diet may be useful for in vivo
pre-clinical assessment of novel therapies.
Introduction
Alcohol related liver disease is responsible for about a third of all liver transplants, and 40% of
liver-related deaths in the US [1, 2]. In addition to continued efforts to tackle alcohol use disor-
der (AUD) it is also important to develop pharmacological interventions designed to reduce
both alcohol-induced liver disease (ALD) incidence, and mortality. Development of effective
ALD therapies, as a result, must rely on rodent models that closely recapitulate ALD pathology.
Diet is a major contributing factor to the progression and severity of non-alcohol induced
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steatohepatitis (NASH). Diet and ALD etiopathology and severity are irrevocably linked [3, 4].
However, pre-clinical rodent models of alcohol-induced steatohepatitis (ASH) do not typically
account for the influence of diet. Binge drinking and chronic alcohol misuse are also associated
with unhealthy eating habits such as intake of high-calorie processed foods [3, 5, 6]. Obesity
and metabolic diseases including diabetes, cardiovascular disease and dyslipidemia are dispro-
portionately prevalent in AUD patients [3]. The likelihood of a prognosis of ALD, steatosis,
acute alcoholic hepatitis and cirrhosis is strongly associated with being overweight for at least
10 years [7, 8]. Obesity and alcohol abuse also synergistically enhance the risk of hepatocellular
carcinoma [4, 8, 9]. Also, ethanol results in more severe hepatic pathology, dysregulated glu-
cose metabolism and altered lipid metabolism in obese (ob/ob) mice [10]. Chronic ethanol
exposure also promotes adipose tissue inflammation and altered adipokine expression which
influences the innate and adaptive immune systems, and contributes to insulin resistance [4].
All these findings point to the synergistic interaction of alcohol, diet, metabolic disease and
ALD. However, it is not completely clear whether the hepatotoxic effects of alcohol consump-
tion are merely additive to NASH, the hepatic symptom of metabolic dysregulation. Also, the
combined physiological impact of the dietary factors that promote ASH, in the absence of obe-
sity or insulin resistance, is unclear. The interaction of diet and alcohol-induced liver disease
also appears complex when alcohol use is moderate [11]. Surprisingly it has been shown that
modest alcohol consumption can suppress NASH which suggests distinct drivers of liver dis-
ease in AUD patients and those that occasionally binge drink or utilize alcohol more sparingly
[11]. Therefore, it is important to develop refined in vivo models that capture this complex
interplay of diet and alcohol use.
The synergistic effects of the western diet, high-calorie binge eating, and chronic alcohol
abuse has, as far as we know, not been comprehensively profiled. We decided to develop mod-
els of ALD/ASH that chronicles the synergistic effects of chronic alcohol use with the western
diet. Here we compared our model to the most well-characterized rodent ASH model, the Lie-
ber-DeCarli (LD) diet, typically used to model acute and chronic alcohol exposure in mice [12,
13]. The LD-diet is nutritionally balanced, therefore, it does not account for the contribution
of high fat, refined sugar and cholesterol to ASH. Also, the LD-diet model does not produce
hepatic fibrosis, a tenet of ALD in humans. To display hepatic fibrosis, mice on the LD-diet
often require a “second-hit” such as a toxicant or inflammatory mediator [14, 15]. Our western
ASH diet model (WASH-ethanol diet) was therefore designed to attempt to account for the
contribution of diet to ALD and more closely mirror the severe hepatic fibrogenesis observed
in humans.
Through our investigations we have found that mice placed on a chronic WASH-diet,
showed accelerated progression to hepatomegaly, and steatosis with substantially elevated
serum levels of liver transaminases compared to the that of the LD-diet. Alcohol-induced
liver pathology including micro- and macro- steatoses, hepatic lipid burden and fibrosis
were also severely exacerbated. Surprisingly, we observed that a once-daily high-fat, fructose
and cholesterol (HFFC) meal was sufficient to exacerbate ASH progression in ethanol-fed
mice that received an otherwise nutritionally balanced diet. This implied that even limited
intake of high fat and fructose may be sufficient to exacerbate ALD progression when com-
bined with chronic alcohol use. Lastly, we confirmed that the WASH-diet model can be used
to evaluate novel treatments for ALD. We found that the therapeutic activity of the Liver-
X-Receptor inverse-agonist SR9238, previously evaluated in LD models [16], was conserved
in the WASH-ethanol model. These results collectively reveal that the combination of the
western diet and ethanol exposure can be used to evaluate the efficacy of experimental
therapies.
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Materials and methods
All experimental protocols were pre-approved by and conducted according to the Saint Louis
University School of Medicine Institutional Animal Use and Care Committee (IACUC) guide-
lines approval number: 2372. Euthanasia was performed by carbon dioxide asphyxiation fol-
lowed by cervical dislocation.
Experimental animals
Male 8–10 week old C57BL6J mice (72 total) were purchased from Jackson Laboratories. Mice
were single-housed and maintained on 12/12 h light/dark cycle.
WASH and Leber DeCarli diet
Feeding protocols followed the guidelines established by NIAAA [12]. Mice were randomly
assigned to groups and acclimated to single housing conditions for one week then weaned
from standard chow onto Leber-DeCarli (BioServ, Frenchtown, NJ) or WASH liquid diets
(Table 1). The listed components for each diet were mixed into 1L of water. Mice were gradu-
ally weaned onto ethanol starting at 0% and increased by 0.9% every two days for 10 days until
a concentration of 4.5% (vol/vol) was reached (Day 0). Body weight was monitored daily. Pair-
fed control groups were given equivalent volumes (~20mL) to that of WASH and LD ethanol
groups. In pair-fed control diets dextran-maltose was used as a substitute for ethanol-derived
calories. Mice were euthanized via CO2 asphyxiation followed by cervical dislocation after
being on ethanol or control diets for 5 or 7 weeks after Day 0.
SR9238-dosing. Mice (n = 10) were maintained on WASH diets +/- 4.5% ethanol for 2
weeks prior to receiving 30mg/kg SR9238 or 10:10:80 vehicle control (10% DMSO: 10%
Tween80: 80% PBS) via intraperitoneal injection once daily for 4 weeks as described [17].
HFFC once-daily binge-meal. Mice (n = 10 per group) were placed on the LD diet +/-
4.5% ethanol and received two 400 mg compressed food pellets that comprised all the
Table 1. Composition of the high fat, fructose and cholesterol “western” alcohol-induced steatohepatitis diet (WASH) compared to the standard Lieber-DeCarli
diet.
COMPONENT LD-CONTROL (G/L) LD-ETHANOL (G/L) WASH-CONTROL (G/L) WASH-ETHANOL (G/L)
ETHANOL - 4.5% v/v - 4.5% V/V
MALTOSE - - 8 8
CHOLESTEROL - - 4.6 4.6
FRUCTOSE - - 34.3 34.6
PRIMEX - - 39.6 39.6
MALTODEXTRIN 115 24.3 - -
SUSPENDING AIDS 6.75 6.75 6.75 6.75
CORN OIL 8.5 8.5 - -
OLIVE OIL 28.4 28.4 - -
SAFFLOWER OIL 2.7 2.7 - -
CASEIN 41.4 41.4 41.4 41.4
VITAMIN MIX 2.5 2.5 2.5 2.5
DL-METHIONINE 0.3 0.3 0.3 0.3
CELLULOSE 10 10 10 10
CHOLINE BITARTRATE 0.5 0.5 0.5 0.5
MINERAL MIX 8.8 8.8 8.8 8.8
L-CYSTINE 0.5 0.5 0.5 0.5
https://doi.org/10.1371/journal.pone.0249316.t001
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components of the WASH diet, except water (Table 1); or two 400 mg pellets of standard
chow. Each mouse was given two pellets at the beginning of the dark cycle and given 2 h to
consume the pellets before being placed in a fresh cage.
Real-time quantitative PCR
Total RNA was isolated from frozen liver tissue using Tri-reagent and reverse transcribed
using the iScript cDNA synthesis kit (Quanta). cDNA was assessed for gene expression using
cognate primers via RT-QPCR.
Body composition analysis
Mice were randomized into weight-matched groups (n = 8) that received the WASH or LD-
control diet alone or with ethanol (Table 1). Body composition was analyzed using a Bruker
BioSpin LF50 Minispec NMR. Mice were weight before being assessed via NMR. Baseline
body composition was analyzed prior to ethanol feeding. Body composition was assessed again
at conclusion of the experiment; after mice were on the respective diets 5 or 7 weeks.
Clinical chemistry
Whole blood was collected following euthanasia via cardiac puncture and serum was isolated
by centrifugation in heparin coated tubes at 15000rpm at 4˚C. Serum was then assessed for
lipid and liver toxicity markers using the Cobas c111 instrument (Roche Diagnostics) and cog-
nate bioassay kits.
Histology
Liver sections were excised from the left lateral lobes, fixed in 10% neutral buffered formalin
overnight and then embedded in paraffin for sectioning. Tissues cut into 10μm-think sections
and mounted on slides and stained with hematoxylin and eosin or subjected to histological
assays listed below.
Masson tri-chrome staining. Paraffin sections of the left lateral lobe were de-paraffinized
and hydrated with deionized water and stained with Bouin’s Solution, Wiegerts Iron Hema-
toxylin and Biebrich Scarlet-Acid Fuchsin as per manufacturer’s instructions (Sigma-Aldrich).
PicoSirius Red staining. 10μM sections were stained with Pico Sirius Red using the
Direct Red-80 kit (Sigma) and assessed for collagen using light microscopy. Collagen staining
(Red) was quantified using ImageJ.
Immunohistochemistry. FFPE slides were deparaffinized in xylene and rehydrated in
ethanol. After performing antigen retrieval using DIVA de-cloaker (Biocare Medical) and
blocking with 5% donkey serum, sections were washed and incubated with primary antibodies
(anti-TGF-B 1:1000; anti-IL6 1:200) overnight at 4˚C. Sections were washed and treated with
secondary HRP-conjugate (donkey anti-rabbit 1:300) for 1 hr. Sections were then incubated
with DAB substrate until desired staining was achieved (45s-1min) and counterstained with
hematoxylin. Slides were dehydrated and mounted prior to imaging
Immunoblots
Total protein was isolated from flash-frozen liver tissue using RIPA buffer (IL6, TGFB) and
run on a 2–10% gradient gel and transferred to a PVDF membrane. For collagen quantifica-
tion protein lysates were isolated from frozen liver tissue using 0.075M citrate buffer (pH 6)
and resolved using 2–8% gradient gel and transferred to PVDF under non-denaturing condi-
tions. Membranes were blocked with 4% BSA and probed with antibodies against TGFB
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(Abcam, ab92486) IL6 (Santa Cruz Biotechnology: (m-19), sc-1265) HSP90 (Cell signaling,
#4874) or COL1A1 (Abcam, ab34710). Protein expression was quantified and normalized to
HSP90 using ImageJ. Latent TGFB-L (44kDa) and mature TGFB-M (13kDA) were detected
using the same antibody (ab92486). For fold-expression of proteins expression from ethanol
fed from mice was normalized to pair-fed controls.
BODPIY staining. The right lateral lobes if isolated livers were placed in 4% PFA over-
night and then transferred to 10% sucrose in PBS for 2 days followed by 20% sucrose in PBS
for another 2 days and finally 30% sucrose in PBS for cryoprotection. These tissues were then
embedded in OCT and frozen in 2-methylbutane dry ice bath. 10um sections were floated in
6-well dishes containing 1X PBS and Bodipy 493/503 (Molecular Probes) staining as described
previously. Floated sections were stained and mounted on slides prior then counterstained
with DAPI.
Statistical analysis
Significant differences between mean body mass, liver weight to body rate ratios and body
composition parameters were all determined using 2-Way ANOVA with multiple compari-
sons. For body composition analysis, group sample sizes (n = 8) were determined using power
set at 0.8 with alpha set to 0.05 to detect differences in mean of 4% and a standard deviation of
approximately +/-2.5% resulting in the calculated sample size of n = 8. For mice treated with
SR9238 the estimated intergroup difference in mean gene expression was 0.4 with standard
deviation of +/-0.3 so the sample size was set to n = 10 for these studies. Clinical chemistry
markers, mRNA (RT-QPCR) and protein (western blot, IHC) expression was compared using
1-Way ANOVA or student’s t-test where relevant. �p<0.05, ��p<0.01���p<0.001. All graphs
were generated and analyzed for significant differences using Prism.
Results
Hepatic toxicity is synergistically increased by the combination of dietary
fat and fructose with ethanol
In order to capture the effects of diet on ASH pathology we characterized the hepatic effects of
a high fat, cholesterol and fructose diet on the backdrop of chronic alcohol intake. Previous
groups have studied the effect of obesity of ASH pathology [4, 10, 18–20]. We wanted to probe
the contribution of macro-nutrient intake, typical of western diets, on ASH progression prior
to the onset of obesity. We formulated the western-ASH (WASH) diet to comprise elevated
amounts of cholesterol (4.6 g/L), trans-fat (39.6 g/L) and fructose (34.3 g/L) (Table 1) as well as
the calorically equivalent control diet supplemented with maltose, corn, safflower and olive oil
as cognate macronutrient controls for fructose and vegetable-derived trans-fat (Primex). We
compared the hallmarks of ALD hepatic pathology in mice fed either the standard chow, Lie-
ber-DeCarli (LD) diet or WASH-diet with or without chronic 4.5%(v/v) ethanol for 5 or 7
weeks (n = 8). The average total body weight of all mice in the study were within normal range
(22-28g) for 8–10 week-old mice (Fig 1A). There were no significant differences in body
weight in mice placed on the LD or WASH-Diet after 5 weeks (Fig 1A). However, mice receiv-
ing the WASH-diet showed an increase in total body weight after 7 weeks compared to LD-
diet mice (Fig 1A right panel). The liver to body weight ratios, a marker of hepatomegaly, in
mice receiving the WASH-diet plus 4.5% ethanol was significantly greater than that of LD-eth-
anol mice (Fig 1B). This indicated that liver injury in WASH-ethanol diet mice was more pro-
nounced. NMR assessment of body composition showed that all mice displayed a shift toward
adiposity regardless of diet (Fig 1C) after 5 weeks. However, at 7 weeks while the shift in
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adiposity was conserved, mice fed WASH-ethanol displayed a significant increase in percent-
age fat mass compared to that of LD-ethanol animals (Fig 1D). Similarly, ethanol-fed groups
showed a reduction in lean mass regardless of diet at both 5 and 7 weeks (Fig 1E and 1F). Nota-
bly ethanol did not significantly reduce lean mass in WASH-ethanol mice compared to LD-
ethanol mice (Fig 1E and 1F). The observations suggested collectively that the lipid and fruc-
tose burden of the WASH-ethanol diet had a additively deleterious effect on liver injury and
whole body adiposity that exceeded that of the LD diet.
Serum cholesterol, triglycerides and markers of liver injury are
significantly elevated by the WASH-ethanol diet
We evaluated the changes in lipid metabolism and determine whether clinical markers of liver
injury correlated with our previous findings. Liver triglycerides (TGs) were significantly higher
in WASH-ethanol mice at 5 and 7 weeks compared to LD-ethanol mice (n = 8) (Fig 2A and
2B). At 5 weeks, plasma cholesterol was only increased in WASH-ethanol mice compared to
WASH-controls, and relative to LD-diet mice (Fig 2C). Similarly, at 7 weeks both LD- and
WASH-ethanol groups showed significantly increased cholesterol compared to their cognate
controls (Fig 2D). At 5 weeks circulating levels of alanine amino-transferase (ALT) in WASH-
ethanol mice exceeded that of WASH-controls but LD-ethanol mice showed no significant
increase (Fig 2E). Two weeks after LD-ethanol mice did not display elevated ALT. However,
WASH-ethanol mice showed a robust rise in ALT at 7 weeks (Fig 2F). Conversely, aspartate
aminotransaminase (AST) were significantly elevated in mice receiving WASH-ethanol com-
pared to pair-fed controls and LD-ethanol mice at 7 weeks but not after 5 weeks (Fig 2G and
2H). These results suggest that the WASH-ethanol diet produces accelerated liver toxicity and
pronounced disruption of hepatic lipid metabolism that may contribute to more severe liver
pathology compared to the LD-ethanol diet.
The WASH-ethanol diet produces pronounced hepatic steatosis and
accelerated lipid accumulation
To determine whether the WASH-ethanol and LD-ethanol differentially influenced liver
pathology, we performed hematoxylin eosin (H&E) staining on liver sections from mice
exposed to these diets +/- ethanol. At 5 weeks the WASH-control mice displayed minor
micro-steatosis that partly extended into the intermediary region between to lobule arteries
and veins (Zone 2) (Fig 3A). As expected in the LD-ethanol group there was visible micro and
macro-steatoses that extended into the intermediate region (Zone 2) (Fig 3A). LD-controls
displayed restricted micro-steatosis that did not extend past the hepatic lobule periphery
(Zone 1) into the intermediate zone. In contrast, WASH-ethanol mice displayed significantly
more severe liver morphology with macro and micro-steatosis extended into the periphery of
the portal vein (Zone 3) (Fig 3A). At 7 weeks WASH-ethanol diet caused more pronounced
and extensive macro-steatosis (Fig 3B). Liver sections were also assessed for lipid content
using BODIPY neutral lipid staining. The combination of the WASH diet and ethanol syner-
gistically increased hepatic dyslipidemia compared to pair-fed controls and LD-ethanol mice
Fig 1. Ethanol combined with fat, cholesterol and fructose promotes hepatomegaly and whole-body adiposity. A. Total body weight of mice placed on the
Lieber De-Carli (LD) or Western/Alcohol Steatohepatitis diet (WASH) with (LD-Ethanol, WASH-Ethanol) or without 4.5% ethanol for 5 weeks (left panel) or 7
weeks (right panel) B. Liver to body weight rations of mice fed the LD and WASH ethanol or cognate control diets for 5 or 7 weeks. C. Percent fat mass of mice fed
LD and WASH diets for 5 weeks or D. 7 weeks E. Percentage fat-free lean mice in mice fed the LD and WASH diets for 5 or F.7 weeks. Body composition
measured using BrükerSpin mini spec rodent NMR. Sample size is n = 8 per group. Means compared using One-Way ANOVA. �p<0.05. +/- standard error of the
mean (S.E.M).
https://doi.org/10.1371/journal.pone.0249316.g001
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Fig 2. Ethanol induced liver toxicity is exacerbated by the WASH diet. A. Serum triglyceride (TG) levels in mice
placed on the LD and WASH diets +/- ethanol for 5 or B. 7 weeks. C. Total circulating cholesterol in mice fed the
WASH or LD diets+/- ethanol for 5 or D. 7 weeks E. Serum alanine amino transferase (ALT) levels in mice fed the
WASH and LD diets +/- ethanol for 5 weeks or F. 7 weeks. G. Serum aspartate amino transferase (ALT) levels in mice
fed the WASH and LD diets +/- ethanol for 5 weeks or H. 7 weeks. Serum was isolated from cardiac blood. Serum
levels of lipids and proteins were determined using a Cobas C11 clinical chemistry bioanalyzer (Roche Diagnostics).
(n = 8 mice per group). Mean levels were compared using One-Way ANOVA. � p<0.05, ��p<0.01 ���p<0.001 +/- S.E.
M.
https://doi.org/10.1371/journal.pone.0249316.g002
Fig 3. Hepatic lipid content is elevated in mice fed the WASH-ethanol diet. A. Hematoxylin and eosin (H&E) staining of liver sections from fed the LD and
WASH diets +/- ethanol for 5 weeks B. 7 weeks C. BODIPY neutral lipid staining of liver samples from mice receiving the LD and WASH ethanol diet +/-
ethanol for 5 or D. 7 weeks. Representative images from sections analyzed from 8 mice (n = 8). Left (H&E) or right (BODIPY) lateral lobes were stained as
described in the materials and methods section.
https://doi.org/10.1371/journal.pone.0249316.g003
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at 5 weeks that became more sever at 7 weeks (Fig 3B and 3C). These results highlight that the
high fat/fructose and ethanol had synergistic effects on liver pathology and lipid metabolism
when combined with ethanol.
Combined dietary fat, fructose and ethanol produces extensive liver
fibrosis
One limitation of the LD-ethanol model is that it does not intrinsically lead to hepatic fibrosis
which is a hallmark of human ASH. We therefore assessed collagen deposition using Masson
Trichrome Staining in the livers of mice fed the WASH and LD diets +/- ethanol. At 5 weeks
neither mice placed on the LD-ethanol or WASH-ethanol diet displayed fibrosis. Interestingly,
mice receiving the WASH-ethanol diet had extensive fibrosis at 7 weeks, based on Masson tri-
chrome staining, which was not observed in other groups (Fig 4A and 4B). Hepatic collagen
protein (COL1A1) levels was also elevated in WASH-ethanol compared to WASH-control
mice (Fig 4D). In addition, hepatic protein levels of the inflammatory factors IL6 and TGFB
were only increased in mice placed on the WASH-ethanol diet for 7 weeks (Fig 4E and 4F).
These findings imply that the fat and fructose in the WASH diet may be sufficient “second-
hits” for effectively driving hepatic inflammation and fibrinogenesis.
Restricted feeding of high fat, cholesterol and fructose accelerates chronic
alcohol-induced liver damage
Considering the metabolic burden of chronic high fat/fructose intake in the WASH diet we
decided to explore whether restricted bouts of once daily high fat/fructose meals was sufficient
to exacerbate the effect of chronic ethanol intake on liver pathology. We formulated a, high-
fructose trans-fat and cholesterol meal (HFFC), which comprised the same macronutrients as
the WASH diet (Table 1). We then designed a study to explore the effect of restricted once
daily intake of calorie-rich, but micronutrient-deficient, meals on ALD progression. 8-week-
old, C57BL6/J male mice were placed on the LD-ethanol or LD-control diet and given two
400mg HFFC or standard chow pellets once a day during a 2 h time window for 4 weeks. Inter-
estingly, mice receiving the HFFC pellets displayed more severe liver pathology with acceler-
ated development of steatosis (Fig 5A). These HFFC meals also stimulated greater hepatic lipid
accumulation compared to pair-fed controls (Fig 5B). There results suggested that even limited
daily dietary intake of high fat, cholesterol and fructose meals can contribute to ALD progres-
sion when combined with high alcohol intake.
The WASH model can be used to evaluate experimental therapies for ALD
We have previously shown that the inverse agonist of the Liver-X-Receptor SR9238 potently
reduces hepatic lipogenesis and slows the progression of NASH and ALD [16, 17]. To deter-
mine whether the WASH model was a useful model system for evaluating the efficacy of exper-
imental drugs we tested the efficacy of SR9238 in mice receiving the WASH-ethanol diet or
pair-fed controls (Fig 6 and S1 Fig). Mice were placed on the WASH diet for 2 weeks then
Fig 4. WASH-ethanol diet fed mice show worsened liver pathology and amplified fibrosis. A. Masson Trichome staining of liver sections isolated
from mice exposed to the WASH or LD diet +/- ethanol for 5 or B. 7 weeks. Trichrome staining was performed on left lateral lobe liver sections that
were formalin fixed paraffin embedded. Representative image (n = 8). C. Immunoblot showing expression of latent and mature (TGFB-L and
TGFB-M respectively), IL6 and HSP90 in mice placed on their respective diets for 7 weeks. D. Fold protein expression of TGFB-L, TGFB-M and IL6
in mice placed on the LD or WASH control or ethanol diets for 7 weeks. Target proteins normalized to HSP90 and represented as fold increase
relative to LD- and WASH-Diet Pair-fed controls. OD quantified in ImageJ. E. Immunoblot showing collagen expression (COL1A1) in LD and
WASH control versus ethanol-fed mice at 7 weeks. F. Quantified expression of COL1A1 normalized to HSP90 in the samples shown in E. Means
compared using student’s t-test �p<0.05 ��p<0.01. +/- S.E.M.
https://doi.org/10.1371/journal.pone.0249316.g004
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dosed with 30mg/kg SR9238 via intraperitoneal (i.p.) injection once a day for 4 weeks. As
expected, based on previous investigations [16] liver pathology was significantly improved in
mice receiving SR9238 (Fig 6A). In WASH-ethanol mice SR9238 reduced hepatic IL6 and
TGFB protein expression (Fig 6B and 6C). Pico Sirius Red staining also revealed that SR9238
reduced hepatic fibrosis in WASH-ethanol mice (Fig 6D). Although the hepatic fibrosis
observed was not as severe as that of mice placed on the diet for 7 weeks (Fig 4B). Improved
liver pathology coincided with a significant reduction Liver-X-Receptor (LXR) target-gene
expression including enzyme and transcriptional mediators of hepatic lipogenesis such as fatty
acid synthase (Fasn) and sterol-regulatory element binding protein 1c (Srebp1c) and LXR
(Nr1h2 and Nr1h3) (Fig 6E). Expression of Tnfa and Tgfb was also similarly downregulated in
SR9238 treated mice indicating that LXR inhibition was able to mitigate hepatic inflammatory
signaling at a transcriptional level (Fig 6F). In tandem with these findings liver toxicity mark-
ers were reduced to normal levels in mice treated with SR9238 (Fig 6G). These findings con-
firmed that SR9238 displayed comparable therapeutic efficacy in the WASH as observed in the
classic LD models and LD-ethanol binge models [16]. These results reveal that the WASH
model may be a useful model for exploring the therapeutic activity of newly developed phar-
macological agents.
Conclusions
In this study we developed an ALD model that combines chronic alcohol intake with the meta-
bolic burden of the western diet to quantify the combined effect high fat, cholesterol, fructose
and alcohol abuse. We show here that our WASH diet significantly exacerbates ALD patho-
genesis and produces pronounced steatohepatitis, inflammation and fibrosis compared to that
the LD-ethanol diet. Further we highlight that even if only limited to once daily intake, feeding
mice on the LD-base diet high fat and fructose meal pellets promoted more severe hepatic dys-
lipidemia compared to the LD-ethanol diet alone. This observation was particularly interesting
considering consumption of fast food rich in saturated fat and fructose is commonly associated
with binge drinking. There are no reported studies that probe the combined biological effect
of binge drinking and fast food intake. Whether the HFFC model could be used to map the
acute or long term physiological consequences of ingesting fast food after binge drinking is
unclear and should be explored.
The development of the ALD models in mice such as the Lieber-DeCarli diet have allowed
investigators to explore the mechanisms that drive ALD. Classic LD models, however, are
unable to accurately recapitulate ALD in humans. Specifically, LD models do not develop
fibrosis and never progress to cirrhosis. Liver fibrosis in LD-mouse models is often limited
and requires a “second-hit” such as carbon tetrachloride or inflammatory insult (e.g., IL6) in
order to produce detectable hepatic fibrosis. Other approaches utilize forced-feeding or alcohol
binges which require surgical procedures that come with increased risk of acute alcohol toxic-
ity or surgical complications that contribute to increased mortality in experimental animals
[12]. Conversely while the role of dietary fat intake is known to contribute to ALD pathogene-
sis and mortality in humans, few rodent models employ dietary fat as a secondary insult. How-
ever, while we observed increased fibrinogenesis and inflammation, it is important to note that
Fig 5. Once-daily high fat, fructose and cholesterol meals (HFFC) significantly altered ethanol induced liver pathology. A.
H&E staining of liver sections of mice fed the LD-diet +/- ethanol with or without a once daily meal of two 400mg high fat fructose
and cholesterol (HFFC) or control pellets between 1200 and 1400 h daily. B. BODIPY-neutral lipid staining of liver sections
showing the lipid content of the livers from mice on the LD-diet +/- ethanol with HFFC pellets or control chow pellets.
Representative slides (n = 10). Mice we allowed to ingest HFFC pellets of chow pellet controls for 2 h before being transferred to a
fresh cage.
https://doi.org/10.1371/journal.pone.0249316.g005
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Fig 6. The WASH-ethanol diet model can be used to evaluate the effect of novel drugs on liver, toxicity, pathology and fibrogenesis. A.
H&E staining of liver sections of mice (n = 10) placed on the WASH-ethanol diet and dosed with 30mg/kg SR9238 or vehicle control (10:10:80
DMSO:Tween80:PBS) Representative images (n = 10). Mice were placed on the WASH diet +/- ethanol for 2 weeks before dosing began. SR9238
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the most pronounced synergistic effect of alcohol and high fat was on steatosis in the
WASH model described here. This suggest that disrupted hepatic lipid metabolism may be an
important pathophysiological component to ALD that should be leveraged in rodent ALD
diets.
Our collective understanding of the toxic effects of alcohol on hepatic function and physiol-
ogy is growing. However, there are few treatments other than behavioral changes such as absti-
nence available to chronic alcohol abusers, as many patients are ineligible for liver transplant.
In some cases, advanced liver disease can continue to progress despite abstinence. Considering
the formidable psychological challenge and the high rate of recidivism for alcohol addiction,
hepatoprotective treatments are going to become increasingly important for addressing these
clinical challenges. Lastly hepatoprotective drugs may provide reprieve and valuable time for
patients struggling with alcohol addiction. Studies such as this that attempt to improve on the
current rodent models of ASH will lead to more refined targeted treatments that could help
address these clinical challenges long term.
As mentioned, it is difficult to produce fibrosis in mouse models of ALD without the utili-
zation inflammatory mediators or toxic factors. Cirrhosis and hepatocellular carcinoma, the
penultimate causes of mortality in humans has not been documented in any mouse ethanol
diet models. In humans ALD is typified by hepatic fibrosis that eventually progresses to cirrho-
sis which is a precursor to malignant disease. In this study pronounced fibrosis was induced in
the WASH-ethanol model in 7 weeks. Whether mice fed the WASH-ethanol diet can be
induced to develop cirrhosis or carcinoma is unknown and should be the subject of future
study. It also remains to be determined whether enhanced dietary lipid burden in other mouse
models of hepatic fibrinogenesis, such as choline-deficient diets, can be modified to produce
not only severe fibrosis, but potentially cirrhosis and carcinogenesis. Importantly in these
potential models the ethical concerns of exposing mice to ethanol for protracted periods of
time must be weighed against the import and impact of a mouse model of alcohol-induced cir-
rhosis and cancer.
Dyslipidemia and adipogenesis are largely associated with the development and severity of
ALD. Interestingly, brown adipose tissue activation has been shown to be hepatoprotective in
models of ALD in contrast to white adipose tissue [21]. The mice in our studies did not
become obese but displayed high adiposity (WAT) (Fig 1). However, we did not quantify the
relative composition of brown versus white adipose tissue in this study. Whether BAT or
WAT localization or activation influences the severity of ALD should be explored.
ASH and ALD are complex physiological conditions that are influenced by metabolic activ-
ity, inflammation and the gut microbiome. Recreating, and probing the interplay of these sys-
tems should be central to enhancing our understandings of the mechanisms that drive
alcohol-induced hepatic pathogenesis. The gut microbiome is heavily influenced by diet.
Therefore, further studies should continue explore how diet and alcohol abuse in combination
influence the composition of the gut microbiome and ALD pathology.
or vehicle was administered via i.p. once daily for 4 weeks. B. Immunohistochemistry (IHC) showing expression IL6 in the livers of vehicle versus
SR9238 dosed mice. Representative images (n = 10). C. IHC expression of TGFB in vehicle and SR9238 treated mice. Representative images
(n = 10). D. PicoSirius Red staining showing hepatic collagen deposits in livers of mice treated with SR9238 or vehicle. (Lower panel) Percent
area of collagen positive staining in WASH-diet + ethanol-fed mice treated with SR9238 or vehicle. PicoSirius Red staining was quantified using
image J. Representative image (n = 10) D. Liver-transaminases (ALP, AST and ALT) in mice fed the WASH-ethanol diet and dosed with SR9238.
Liver transaminase levels were quantified using the Cobas C11 bioanalyzer and cognate assay kits (n = 8). E. RT-QPCR showing expression of the
LXR isotypes Nr1h3, Nr1h2, Fatty-acid synthase (Fasn) and Sterol-regulatory element binding protein-1c (Srebp1c). F. Hepatic mRNA expression
of Tnfa and Tgfb in vehicle and SR9238 dosed mice. Total mRNA was isolated from flash frozen liver sections and gene expression was quantified
using cognate primers. Mean values were compared using student’s-t test. �p<0.05 +/- S.E.M.
https://doi.org/10.1371/journal.pone.0249316.g006
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Supporting information
S1 Fig. Quantification of inflammation and fibrinogenesis in WASH-diet pair-fed control
mice display. A. IHC expression of TGFB in vehicle and SR9238 treated WASH-control diet
fed mice. B. IHC expression of IL6 in mice receiving the WASH-control diet and dosed with
vehicle or SR9238 C. PicoSirius Red staining showing lack of hepatic collagen deposits in livers
of WASH control mice treated with SR9238 or vehicle. Immunohistochemistry was performed
as described in the materials and methods section.
(PDF)
Author Contributions
Conceptualization: Kristine Griffett, Thomas P. Burris, Colin A. Flaveny.
Data curation: Monideepa Sengupta, Suomia Abuirqeba, Amina Kameric, Aurore Cecile-Val-
fort, Colin A. Flaveny.
Formal analysis: Amina Kameric, Colin A. Flaveny.
Funding acquisition: Thomas P. Burris, Colin A. Flaveny.
Investigation: Monideepa Sengupta, Suomia Abuirqeba, Colin A. Flaveny.
Methodology: Suomia Abuirqeba, Kristine Griffett, Colin A. Flaveny.
Project administration: Monideepa Sengupta, Colin A. Flaveny.
Resources: Arindam Chatterjee, Thomas P. Burris, Colin A. Flaveny.
Supervision: Thomas P. Burris, Colin A. Flaveny.
Writing – original draft: Colin A. Flaveny.
Writing – review & editing: Colin A. Flaveny.
References
1. Report—Alcohol-Attributable Fractions, US, Excessive Use. [cited 20 Nov 2020]. Available: https://
nccd.cdc.gov/DPH_ARDI/Default/Report.aspx?T=AAF&P=1A04A664-0244-42C1-91DE-
316F3AF6B447&R=B885BD06-13DF-45CD-8DD8-AA6B178C4ECE&F=&D=
2. Publications | National Institute on Alcohol Abuse and Alcoholism | Surveillance Report #113. [cited 20
Nov 2020]. Available: https://pubs.niaaa.nih.gov/publications/surveillance113/CONS17.htm
3. Kirpich IA, Miller ME, Cave MC, Joshi-Barve S, McClain CJ. Alcoholic liver disease: Update on the role
of dietary fat. Biomolecules. MDPI AG; 2016. pp. 2–17. https://doi.org/10.3390/biom6010001 PMID:
26751488
4. Chiang DJ, McCullough AJ. The impact of obesity and metabolic syndrome on alcoholic liver disease.
Clinics in Liver Disease. NIH Public Access; 2014. pp. 157–163. https://doi.org/10.1016/j.cld.2013.09.
006 PMID: 24274871
5. Hwang S, Ren T, Gao B. Obesity and binge alcohol intake are deadly combination to induce steatohe-
patitis: A model of high-fat diet and binge ethanol intake. Clinical and Molecular Hepatology. Korean
Association for the Study of the Liver; 2020. pp. 586–594. https://doi.org/10.3350/cmh.2020.0100
PMID: 32937687
6. Chang B, Xu MJ, Zhou Z, Cai Y, Li M, Wang W, et al. Short- or long-term high-fat diet feeding plus acute
ethanol binge synergistically induce acute liver injury in mice: An important role for CXCL1. Hepatology.
2015; 62: 1070–1085. https://doi.org/10.1002/hep.27921 PMID: 26033752
7. Dyson J, Jaques B, Chattopadyhay D, Lochan R, Graham J, Das D, et al. Hepatocellular cancer: The
impact of obesity, type 2 diabetes and a multidisciplinary team. J Hepatol. 2014; 60: 110–117. https://
doi.org/10.1016/j.jhep.2013.08.011 PMID: 23978719
PLOS ONE A two-hit model of alcoholic liver disease that exhibits rapid, severe fibrogenesis
PLOS ONE | https://doi.org/10.1371/journal.pone.0249316 March 26, 2021 16 / 17
8. Jump DB, Depner CM, Tripathy S, Lytle KA. Impact of dietary fat on the development of non-alcoholic
fatty liver disease in Ldlr-/- mice. Proceedings of the Nutrition Society. Cambridge University Press;
2016. pp. 1–9. https://doi.org/10.1017/S002966511500244X PMID: 26282529
9. Hassan MM, Hwang LY, Hatten CJ, Swaim M, Li D, Abbruzzese JL, et al. Risk factors for hepatocellular
carcinoma: Synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology. 2002; 36: 1206–
1213. https://doi.org/10.1053/jhep.2002.36780 PMID: 12395331
10. Everitt H, Hu M, Ajmo JM, Rogers CQ, Liang X, Zhang R, et al. Ethanol administration exacerbates the
abnormalities in hepatic lipid oxidation in genetically obese mice. Am J Physiol—Gastrointest Liver Phy-
siol. 2013; 304: G38. https://doi.org/10.1152/ajpgi.00309.2012 PMID: 23139221
11. Yamada K, Mizukoshi E, Seike T, Horii R, Kitahara M, Sunagozaka H, et al. Light alcohol consumption
has the potential to suppress hepatocellular injury and liver fibrosis in non-alcoholic fatty liver disease.
Aspichueta P, editor. PLoS One. 2018; 13: e0191026. https://doi.org/10.1371/journal.pone.0191026
PMID: 29342182
12. Bertola A, Mathews S, Ki SH, Wang H, Gao B. Mouse model of chronic and binge ethanol feeding (the
NIAAA model). Nat Protoc. 2013; 8: 627–637. https://doi.org/10.1038/nprot.2013.032 PMID: 23449255
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